Compare LMNR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | TLSI |
|---|---|---|
| Founded | 1893 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.6M | 244.3M |
| IPO Year | N/A | N/A |
| Metric | LMNR | TLSI |
|---|---|---|
| Price | $14.00 | $7.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $20.50 | $10.67 |
| AVG Volume (30 Days) | 86.9K | ★ 155.3K |
| Earning Date | 12-22-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,763,000.00 | $40,207,000.00 |
| Revenue This Year | N/A | $55.06 |
| Revenue Next Year | N/A | $46.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $12.69 | $3.42 |
| 52 Week High | $28.17 | $7.32 |
| Indicator | LMNR | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 74.64 |
| Support Level | $13.57 | $6.06 |
| Resistance Level | $14.31 | $7.32 |
| Average True Range (ATR) | 0.36 | 0.55 |
| MACD | 0.13 | 0.18 |
| Stochastic Oscillator | 77.73 | 91.91 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.